The bright future of Alzheimer’s disease pharmacotherapy

Jimma L. Lenjisa\textsuperscript{1}\textsuperscript{*}, Gizaw D. Satessa\textsuperscript{2}, Minyahil A. Woldu\textsuperscript{1}

\textsuperscript{1}Department of Clinical Pharmacy, Ambo University, College of Medicine and Health Sciences, Ambo, Ethiopia, \textsuperscript{2}Department of Pharmacology, Ambo University, College of Medicine and Health Sciences, Ambo, Ethiopia

Received: 30 October 2013
Accepted: 13 November 2013

\textsuperscript{*}Correspondence to: Jimma L. Lenjisa, Email: jimmapharm@gmail.com

© 2014 Lenjisa JL et al. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT
Alzheimer's disease (AD) is the most common cause of progressive dementia in the elderly population leading to progressive disturbances of cognitive functions. It is the disease whose prevalence is rising but with very limited numbers of drugs limiting its progression making more difficult to overcome the evil side of this disease. Currently, there are a number of drugs in pipeline blooming the hope to effectively modify the progression of AD. All of these newer agents are directing toward the biochemical mechanism of AD development including targeting tau protein (e.g. Inhibition of tau kinase), targeting Aβ (e.g. β-Secretase Inhibitors), and therapies involving gene as well as stem cell strategies. Hence in this review, we summarized the pathogenesis of AD on which the discovery of these newer agents based in addition to giving a clear picture on these agents.

Keywords: Alzheimer's disease, Secretase inhibitors, Gene therapy, Stem cell therapy

INTRODUCTION
Alzheimer's disease (AD) is the most common cause of progressive dementia in the elderly population. It is a chronic neurodegenerative disorder that leads to progressive disturbances of cognitive functions including memory, judgement, decision-making, orientation to physical surroundings and language. It has been estimated that \~5% of the population older than 65 years is affected by Alzheimer's disease. The prevalence doubles approximately every 5 years beyond age 65 and some studies suggest that nearly half of the people aged 85 years and older suffer from this devastating disorder.\textsuperscript{1}

In the United States, AD is the sixth leading cause of death, with an estimated 5.3 million Americans having AD. By 2050, according to some estimates, 1 of every 85 persons worldwide will be affected by AD. Currently available treatments for AD provide largely symptomatic relief with only minor effects on the course of the disease.\textsuperscript{2}

The ideal therapies for AD should be not only effectively improving the dementia symptoms but also fundamentally reducing the burden of senile plaques and neurofibrillary tangles and thus protect the neurons from degeneration. Currently several drugs and agents that either affect secretory amyloid precursor degradation, or inhibit amyloid peptides aggregation or block hyperphosphorylated tau protein formation are under investigation in preclinical trials. These new approaches are representatives of current therapeutic development for the treatment of AD.\textsuperscript{3} Thus; this review aims at giving brief account on potential mechanism based therapy that can help modify the pathology of AD as compared to symptomatic therapy.
BIOCHEMICAL BASES OF ALZHEIMER’S DISEASE (AD)

The pathological hallmarks of AD are the accumulation of Aβ as neuritic plaques and congophilic angiopathy and the accumulation of abnormally phosphorylated tau in the form of neurofibrillary tangles (NFTs). Missense mutations in amyloid precursor protein (APP) or in presenilin genes [presenilin 1 (PS1) and PS2] can cause early-onset, familial forms of AD.\(^4\)

1. Amyloid-β (Aβ) accumulation – neuritic plaques

The known genetic forms of AD are caused by mutations in amyloid precursor protein (APP) which is coded on chromosome 21 or the enzymes that are involved in Aβ formation. The pathway for Aβ plaque formation begins with the pathologic processing of APP. This protein is cleaved first by the protease β-secretase (i.e., BACE-1) and subsequently by γ-secretase to form either the benign peptides Aβ\(_{38-40}\) or the neurotoxic peptide Aβ\(_{42}\). Under normal circumstances, the vast majority of Aβ (>95%) consists of Aβ\(_{38-40}\). Through unknown mechanisms, genetic and environmental factors may shift this balance toward increased production of toxic Aβ\(_{42}\). Accumulation and oligomerization of Aβ\(_{42}\) results in the formation of amyloid plaques and initiates a cascade of events associated with neuronal and synaptic dysfunction.\(^5,6\) Figure 2 summarizes these facts.

2. Hyperphosphorylated tau protein accumulation - Neurofibrillary Tangles (NFTs)

AD is also considered a tauopathy due to abnormal aggregation of the tau protein. Every neuron has a cytoskeleton, an internal support structure partly made up of structures called microtubules. A protein called tau stabilizes the microtubules when phosphorylated. In AD, tau undergoes chemical changes, becoming hyperphosphorylated; it then begins to pair with other threads, creating neurofibrillary tangles and disintegrating the neuron’s transport system.\(^7\) Tau pathology develops slowly with increasing age in a large percentage of the population, and this may help explain why age is the major risk factor for AD. Therefore, the pathological hyperphosphorylation of tau, which can be visualized by immunochemical methods, is an early event in the development of Alzheimer’s disease related neurofibrillary changes.\(^8,9\) This is clearly shown on figure 1.

Figure 1: The amyloid hypothesis of Alzheimer’s disease.\(^9\)
TARGET SITES FOR MOST OF THE NOVEL DRUGS IN TREATMENT OF AD

According to the amyloid cascade hypothesis novel therapeutic strategies that lower Aβ levels or prevent the formation of the presumed neurotoxic oligomeric Aβ species (Figure 2) are predicted to stop or slow down the progression of neurodegeneration and dementia in AD.

The figure summarizes the presumed sequence of pathological processes that leads to neurodegeneration in AD according to the amyloid cascade hypothesis, and indicates selected potential approaches for therapeutic intervention.

1. Therapeutic strategies targeting Aβ

A. β-secretase inhibitors

Although the development of β-secretase inhibitors has lagged behind the development of γ-secretase inhibitors, many believe that β-secretase is likely to be a better therapeutic target. β-secretase is an important biological target for new drug development, but clinical trials have not yet been conducted. While inhibition of β-secretase is not expected to incur the same safety risk as γ-secretase inhibitors, BACE-1 deficiency in genetically engineered mice is associated with impaired learning. In addition, there are significant pharmacokinetic challenges in developing a viable BACE inhibitor. To date, the compounds that effectively inhibit BACE activity are large molecules that do not penetrate the blood-brain barrier. Nevertheless, inhibition of β-secretase is a promising strategy. This therapeutic potential was demonstrated by the findings that BACE-1 knockout mice develop normally, and appear to have completely abolished the production of Aβ, suggesting that BACE-1 is the principal β-secretase in neurons. Such inhibition does not preclude normal processing of APP by the nonamyloidogenic major pathway, and is the first step in the amyloidogenic cascade. Specific BACE-1 inhibitors should therefore have therapeutic potential to slow or halt the progression of this debilitating and ultimately fatal disease, and a number of preclinical candidates are about to enter clinical trials.

B. γ-secretase inhibitors

Identification of the protein responsible for γ-secretase activity, the enzyme that cleaves APP within the membrane, has been very challenging. Much evidence indicates that the catalytic activity resides in presenilins (PS1/PS2), proteins with multiple transmembrane domains, as mutagenesis of 2 aspartates in PS1 eliminated γ-secretase activity. The γ-secretase activity is associated with a complex of integral membrane proteins that includes, at least, a novel...
aspartyl protease, presumably PS, and nicastrin, a protein with a single transmembrane domain. Use of difluoroketone-based compounds as γ-secretase inhibitors has provided insights into the proteolytic activity and suggested such inhibition might be a useful therapeutic strategy. Some compounds are currently in phase I clinical trials.15

More progress has been made in developing γ-secretase inhibitors, because high-throughput screens carried out in the pharmaceutical industry have identified numerous γ-secretase inhibitors. Multiple classes of potent γ-secretase inhibitors have now been described, and several of these have been shown to target both PS1 and PS2.16 Moreover, treatment of mice with a γ-secretase inhibitor reduces Aβ levels in the brain and attenuates Aβ deposition.17 Nevertheless, target-mediated toxicity caused by interference with γ-secretase is a great concern.18,19 To tackle this challenge, an attempt is being made in identifying potential targets and highly specific γ-secretase inhibitors that may be translated into the development of efficacious and safe treatments.20,21

C. α-secretase activators

The α-secretase is a member of a disintegrin and metalloprotease (ADAM) family. The initial APP processing involves the cleavage of APP by α-secretase. The identification of proteins with α-secretase activity is ongoing, and currently includes a constitutive activity [a disintegrin and metalloproteinase (ADAM)-10].22 Because the α-secretase cleavage site is within the Aβ sequence of APP, and none of these proteolytic fragments have been associated with the generation of AD, enhanced cleavage at this site may represent a disease modifying strategy for AD as first postulated by Nitsch and colleagues.23

A related strategy to increase the fraction of APP cleaved by α-secretase is to modulate the trafficking of APP in such a way as to increase the likelihood that α-secretase will cleave APP. There are preliminary data that members of the sortin nexin family of proteins can reduce the rate of APP endocytosis, and increase sAPPα production, possibly by exposing the APP substrate to ADAM-10 for an extended period of time. Similarly, strategies that increase the production of ADAM-10 by inhibiting protease inhibitors such as tissue inhibitor of matrix metalloproteinase (TIMP) 1 and TIMP3 may represent further therapeutically tractable approaches to further shift the bias of APP processing from the amyloidogenic to the nonamyloidogenic pathway.3

D. Inhibition of Aβ aggregation

B-sheet breaker that could degrade Aβ is a potential target for AD. Soto and colleagues designed a peptide (iβA11) containing N-terminal domain of Aβ that mainly contributes to Aβ fibrillogenesis. This breaker can bind to Aβ and block the interaction between monomers, oligomers and prevent the formation of amyloid fibrils.24,25

Insulin-degrading enzyme (IDE) is a cytosolic metalloendopeptidase that hydrolyzes numerous peptides with poor substrate selectivity and specificity and was the first protease to be implicated in the proteolytic degradation of Aβ.26 IDE isolated from human brain extracts was demonstrated to cleave Aβ40 and Aβ42 preventing aggregation and neurotoxicity of Aβ in vitro.27 Genetic association with late-onset AD28 and the correlation of high steady-state enzyme levels in brain areas less vulnerable to amyloid pathology in AD support the involvement of IDE in Aβ degradation.29

Neprilysin (NEP) is a 90- to 100-kDa plasma membrane-bound, extracellular, metalloendopeptidase that preferentially hydrolyzes oligopeptidites on the amino terminal of hydrophobic amino acid residues. NEP is expressed in brain and has been demonstrated to hydrolyze Aβ42 in vitro and in vivo.30,31 A 50% reduction of cortical amyloid deposits in transgenic APP mice, after an intracerebral injection of a viral construct expressing NEP, provides further compelling evidence for a potential NEP-mediated Aβ-clearance mechanism in vivo.32 In addition, the recent observation that somatostatin regulates brain Aβ42 levels through the modulation of proteolytic degradation by NEP suggests a potential therapeutic strategy by targeting somatostatin receptors.33

Plasmin, a serine protease released after cleavage of the zymogen plasminogen, can also modulate the clearance of Aβ.34 Kinetic studies measuring the turnover rates of soluble and aggregated Aβ, evaluation of Aβ fibrils by electron microscopy, and Aβ neuroprotection assays in rat cortical cultures, indicate that Aβ is a plasmin substrate in vitro.35,36 Increased plasmin activity may explain reduced Aβ degradation and accumulation of amyloid pathology in AD,37 and strategies to elevate plasmin activity may be of therapeutic relevance.

Several anti-Aβ aggregation agents are currently in clinical testing. Their mechanisms of action vary and are not completely understood, but are believed to involve prevention of fibril formation and facilitation of soluble Aβ clearance. Tramiprosate (Neurochem, Inc.) is a small-molecule glycosaminoglycan (GAG) mimetic. Glycosaminoglycan binds to soluble Aβ, facilitating fibril formation and deposition of amyloid plaque. GAG mimetics compete for GAG-binding sites, thereby blocking fibril formation and reducing soluble Aβ. Colostrinin is a proline-rich polypeptide complex derived from sheep colostrum (O-CLN; ReGen Therapeutics). Colostrinin inhibits Aβ aggregation and neurotoxicity in cellular assays and improves cognitive performance in laboratory animals.38,39

Metal ions like Cu²⁺ and Zn²⁺ may be involved in the mediation of Aβ aggregation and toxicity. A significant decrease in brain Aβ deposition in APP-transgenic mice
was observed after 9 weeks treatment with clioquinol, an antibiotic and Cu/Zn chelator that crosses the blood–brain barrier.\textsuperscript{40,41}

E. Immunotherapy

Immunotherapy has been demonstrated effectively in removal of proteins which accumulate abnormally in animal models of AD and other dementias. Several immunotherapies for AD have been tried in mouse models with transgenic Swedish mutant APP gene.\textsuperscript{42} For most patients, Aβ42 immunization provides effective immune response and promotes amyloid plaques degradation. Immunization with the full-length Aβ42 peptide, containing both B and T cell epitopes, can be more effective in enhancing T cell activation to Aβ clearance. It is desired to have Th2 immune response to promote antibody production and inhibit proinflammatory Th1 response that could activate imiborgulo-induced cytokine release and neurotoxicity.\textsuperscript{43,44}

DNA vaccination may open up a new avenue for treatment of AD. Ghochikyan et al. constructed a DNA minigene with Aβ42 fused to mouse interleukin-4 as a molecular adjuvant to generate anti-Aβ antibodies. This compound successfully enhances the Th2 immune responses and induces the generation of IgG1 and IgG2b Aβ antibodies recognize plaques.\textsuperscript{45} Passive immunotherapy includes administration of specific β amyloid peptide antibodies that would bypass immune response and would not lead to T cell-mediated encephalitis. β-amyloid peptide antibodies (10D5) not only inhibit aggregation of Aβ but also reduce plaque-induced neuritic alterations and cytotoxicity in APP [V717I] transgenic mouse model.\textsuperscript{46}

Three different, though not mutually exclusive, mechanisms have been proposed to explain the amyloid lowering effect of Aβ immunization. Following the detection of antibodies bound to brain amyloid deposits it has been postulated that they trigger FC-receptor-mediated phagocytosis.\textsuperscript{47,48} As an alternative mechanism, the antibodies might act as chaperones and disrupt Aβ aggregates or prevent aggregation.\textsuperscript{49} Finally, circulating antibodies were postulated to sequester Aβ, shift the equilibrium towards the periphery and thereby reduce brain Aβ deposition.\textsuperscript{50}

2. Therapeutic strategies targeting tau

A. Inhibition of tau kinase

Another pathological hallmark of AD is NFTs, which are composed of intracellular filamentous aggregates of hyperphosphorylated MT-associated tau protein, self-conversion into PHF-tau. Numerous mutations of tau gene have been detected in chromosome 17 that is linked to several forms of fronto-temporal dementias.\textsuperscript{51} Dysfunction of tau proteins is responsible for the failure of the self-assembling tau to regulate the MT dynamics that is essential for cell survival. Tau can be phosphorylated by several kinases including glycogen synthase kinase-3β (GSK3 β) and cyclin-dependent kinase 5 (CDK5) that can be regulated by Aβ deposition.\textsuperscript{52,53} Therefore, drugs targeting tau hyperphosphorylation and NFTs may benefit for slowing AD progression. Nearly 20 kinases are reported to phosphorylate tau in vitro; therefore exact identification of the relevant kinase(s) responsible for pathology has proven difficult. The rationale for developing therapeutic inhibitors for cdk-5 and GSK-3 activities has been reviewed elsewhere, but to our knowledge drug discovery studies remain preclinical at this time.\textsuperscript{54,55}

Recent studies evaluating the cascade of events leading to neurofibrillary pathology suggest that hyperphosphorylation of tau by kinases such as cdk-5 and GSK-3 is preceded by phosphorylation of the tau microtubule binding domain by microtubule affinity regulating kinase (MARK). It is suggested that inhibition of MARK may block the event(s) triggering microtubule disruption, tau hyperphosphorylation, aggregation, formation of neurofibrillary tangles and neurodegeneration. Alternative exploratory strategies for reducing tau hyperphosphorylation include increasing the activity phoshatases such as protein phosphatase-2A, thereby promoting the enzymatic dephosphorylation of tau.\textsuperscript{56,57}

B. Activation of phosphatase

The phosphorylation state of any phosphoprotein results from the activities of both, kinases and phosphatases. It has been suggested, that in Alzheimer's disease, an imbalance of kinase and phosphatase activities may lead to abnormal hyperphosphorylation of tau protein. Memantine, an NMDA-receptor antagonist approved for the treatment of moderate to severe Alzheimer's disease was recently reported to inhibit okadaic acid-induced abnormal tau hyperphosphorylation and the associated neurodegeneration in rat hippocampal slices. Interestingly, it was suggested that memantine exerted this effect by restoration of PP2A activity through ‘PP2A signalling’.\textsuperscript{58,59}

3. Gene and stem cell therapy

Since nerve growth factor (NGF) was discovered to rescue cholinergic neurons from apoptosis in 1986, gene therapy with NGF, glial derived neurotrophic factor (GDNF), brain derived neurotrophic factor (BDNF) and nephrilysin for the treatment of AD and related neurodegenerative disorders has been undergoing various experimental and clinical trials. These therapies have been reported not only effective in preventing degeneration of cholinergic neurons but also in ameliorating behavioural deficit and memory impairment in animal models of AD. However, it is a challenge to establish a delivery system that is safe, high efficacy and simple.\textsuperscript{60,61}
Stem cells are another potential resource of therapy for the treatment of AD because of its ability to differentiate into all kinds of neuronal cells. In animal models of AD, stem cell transplantation has showed some promising results in preventing disease progression.\textsuperscript{62,63}

**CONCLUSIONS AND RECOMMENDATIONS**

To sum up, the currently available drugs (ChEIs and memantine) offer symptomatic relief that is temporary at best. New and more durable disease-modifying treatments are needed. The widespread acceptance of the amyloid hypothesis has spurred intense research efforts to identify disease-modifying treatments that interrupt the natural course of Alzheimer’s disease by blocking the pathologic processing of APP to Aβ\textsubscript{42} or enhancing its clearance or decreasing its toxicity. Molecular milestones along the amyloid pathway, including APP, the enzymes involved in generating Aβ\textsubscript{42} (i.e., γ-secretase, β-secretase) or less toxic derivatives (i.e., α-secretase), and Aβ\textsubscript{42} itself, are promising targets for therapeutic intervention. Therefore, prospects for the future of Alzheimer’s disease treatment are very encouraging. The diversity of different therapeutic strategies being explored in clinical trials offers hope. In the not too distant future, disease-modifying treatments will become the standard of care and serve as the springboard for permanently changing the course of Alzheimer’s disease. Last yet most importantly, as this review has explored numerous areas in generating Aβ\textsubscript{40–42}, promising targets for therapeutic strategies being explored in clinical trials need to put this chronic disease under control by halting its progression fully and also attempting a cure as much as possible.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** Not required

**REFERENCES**

1. Hans-Wolfgang Klafki, Matthias Staufenbiel, Johannes Kornhuber and Jens Wiltfang. Therapeutic approaches to Alzheimer's disease. Brain. 2006;129(11):2840–55.
2. Thomas Wisniewski and Allal Boutajangout. Vaccination as a Therapeutic Approach to Alzheimer’s disease. Mount Sinai Journal of Medicine. 2010;77:17–31.
3. Chen S, Zhang XJ, Li L, and Le WD. Current Experimental Therapy for Alzheimer’s disease. Curr Neuropharmacol. 2007June;5(2):127–34.
4. Jacobsen J S, Reinhart P, and Pangalos M. N. Current Concepts in Therapeutic Strategies Targeting Cognitive Decline and Disease Modification in Alzheimer’s disease. Neuro Rx. 2005;2(4):612–26.
5. Perl D. P. Neuropathology of Alzheimer’s disease. Mt Sinai J Med. 2010;77:32–42.
6. Christensen, D.D. changing the course of Alzheimer’s disease: Anti-Amyloid Disease-Modifying Treatments on Horizon. Prim Care Companion J Clin Psychiatry. 2007;9:32–41.
7. Hernández F, Avila J. “Tauopathies”. Cell. Mol. Life Sci. 2007;64(17):2219–33.
8. Michaelis M.R. Drugs Targeting Alzheimer's Disease: Some Things Old and Some Things New. JPET. 2003;304(3):997-904.
9. Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271–8, discussion:278–84.
10. Bartus RT, Dean RL 3rd, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–14.
11. Davies P, Maloney AJ. 1976. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976 Dec;2(8000):1403.
12. Kryger G, Silman I, Sussman JL. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. J Physiol (Lond) Paris. 1999;92:191–4.
13. Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer’s disease. Int Psychogeriatrics. 2002;1:93–126.
14. Wolfe MS. Secretase inhibitors as molecular probes of presenilin function. J Mol Neurosci. 2001;17:199–204.
15. Kopan R and Goate A. A common enzyme connects Notch signaling and Alzheimer’s disease. Genes. 2000;14:2799–2806.
16. Golde, TE, Younkin, SG. Presenilins as therapeutic targets for the treatment of Alzheimer’s disease. Trends Mol. Med. 2001;7:264-9.
17. Doyve, H, Varghese, J, Anderson, JP. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in the brain. J. Neurochem. 2000;76:1-10.
18. De Strooper B et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518-22.
19. Yankner, BA et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer’s disease. Science. 1989;245:417-20.
20. Serneels L, Dejaegere T, and Craessaerts K. et al. Differential contribution of the three A ph1 genes to gamma-secretase activity in vivo. Proc Natl Acad Sci. U S A. 2005;102:1719–24.
21. Barten DM, Guss VL, and Corsa JA. et al. Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor. J Pharmacol Exp Ther. 2005;312:635–43.
22. Lammich S, Kojro E, Postina R, Gilber R, Jasionowski M et al. Constitutive and regulated α-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci. USA. 1999;96:3922–7.
23. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives
stimulated by activation of muscarinic acetylcholine receptors. Science. 1992;258:304–7.
24. Soto C, Kindy MS, Baumann M, Frangione B. Inhibition of Alzheimer’s amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996;226:672–80.
25. Chacon MA, Barria MI, Soto C, Inestrosa NC. Betasheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol Psychiatry. 2004;9:953–61.
26. Kurochkin IV, Goto S. Alzheimer’s β-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 1994;345:33–7.
27. Mukherjee A, Song E, Kihiko-Ehmann M, Goodman JP Jr, Pyrek JS, Estus S, et al. Insulysin hydrolyzes amyloid β peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci. 2000;20:8745–9.
28. Bertram L, Tanzi RE. Alzheimer’s disease: one disorder, too many genes? Hum Mol Genet. 2004;Apr1;13SpecNo1:R135–41.
29. Cacciato A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders. Neurobiol Aging. 2005;26:645–54.
30. Carson JA, Turner AJ. β-Amyloid catabolism: roles for neprilysin (NEP) and other metalloproteinases? J Neurochem. 2002;81:1–8.
31. Iwata N, Tsubuki S, Takaki Y, Watanebe K, Sekiguchi M, Hosoki E, et al. Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6:143–50.
32. Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003;23:1992–1996, 2003.
33. Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM, et al. Somatostatin regulates brain amyloid β peptide specifically interacts with and is degraded by insulin degrading enzyme. Mol Psychiatry. 2004;9:543–52.
34. Periz G, Fortini ME. Proteolysis in Alzheimer’s disease. Can plasmin tip the balance? EMBO. 2001Jan;1(6):477-8.
35. Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, et al. The plasmin system is induced by and degrades amyloid-β aggregates. J Neurosci. 2000;20:3937–46.
36. Tucker HM, Kihiko-Ehmann M, Wright S, Rydel RE, Estus S. Tissue plasminogen activator requires plasminogen to modulate amyloid-β neurotoxicity and deposition. J Neurochem. 2000;75:2172–7.
37. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci. 1997;17:543–52.
38. Gervais F, Chalifour R, and Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid. 2001;8;suppl1:28–35.
39. Rattray M, Technology evaluation: colostrinin, ReGen. Curr Opin Mol Ther. 2005:7:78–84.
40. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, et al. Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 1998;273:12817–26.
41. Cherry RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron. 2001;30:665–76.
42. Weksler ME. The immunotherapy of Alzheimer’s disease. Immun Ageing. 2004;1:2.
43. Hock C, Konietzko U, Streffler JR, Tracy J, Signorell A. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron. 2003;38:547–54.
44. Gellinas D, Salilva K, Fenili D, George-Hyslop P, Mclaurin J. Immunotherapy for Alzheimer’s disease. Proc Natl Acad Sci USA. 2004;101:14657–62.
45. Ghochikyan A, Vasilevko V, Petrushina I, Movsesyan N, Babiykan D. Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol. 2003;33:3232–41.
46. Lombardo JA, Stern EA, Mcellellan ME, Kajdazs ST, Hickey GA, Baucks BJ, Hyman BT, βAmyloid-antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci. 2003;23:10879–83.
47. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–7.
48. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916–9.
49. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci. USA. 1997;94:4109–12.
50. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci. USA. 2001;98:8850–5.
51. Cruts M, Rademakers R, Gijselinck I, van der Zee J, Dermaut B, de Pooter T, de Rijk P, Del-Favero J, van Broeckhoven C. Genomic architecture of human 17q21 linked to frontotemporal dementia uncovers a highly homologous family of low-copy repeats in the tau region. Hum Mol Genet. 2005;14:1753–62.
52. Michaelis ML. Drugs targeting Alzheimer’s disease: some things old and some things new. J Pharmacol Exp Ther. 2003;304:897–904.
53. Li X, Lu F, Tian Q, Yang Y, Wang Q, Wang JZ. Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture. J Neural Transm. 2005;113(1):93–102.
54. Tsai LH, Lee MS, Cruz J. Cdk5, a therapeutic target for Alzheimer’s disease? Biochimica et Biophysica Acta. 2004;1697:137–42.
55. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem. 2004;89:1313–7.
56. Drewes G. Marking tau for tangles and toxicity. Trends Biochem Sci. 2004;29:548–55.
57. Iqbal K, Grundke-Iqbal I. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer’s disease and other tauopathies. Curr Drug Targets. 2004;5:495–502.
58. Mandelkow EM, Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol. 1998;8:425-7.
59. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004;566:261-9.
60. Braddock M. Safely slowing down the decline in Alzheimer’s disease: gene therapy shows potential. Expert Opin Investig Drugs. 2005;14:913–5.
61. Siemer E, Skinner M, Dean RA, Conzales C, Satterwhite J, Farlow M, Ness D, May PC. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 2005;28:126–32.
62. Hughes IA. A perspective on stem cells by a clinician. Eur J Endocrinol. 2004;151(Suppl 3):U3–5.
63. Tanne JH. Activating stem cells may treat Alzheimer’s. BMJ. 2005;330:622.

doi:10.5455/2319-2003.ijbcp20140233
Cite this article as: Lenjisa JL, Satessa GD, Woldu MA. The bright future of Alzheimer’s disease pharmacotherapy. Int J Basic Clin Pharmacol 2014;3:10-7.